Veru Inc is trading at $3.21 (+8.98%) as shares continue to react to a clinical supply agreement with Novo Nordisk for the enobosarm obesity trial.
- The stock remains highly volatile following last week's sharp swings, having reached an intraday high of 11.5% earlier in the session.
- The June 4 announcement regarding the partnership with Novo Nordisk remains the primary catalyst driving the current price action.